Zurex Pharma, a Middleton, WI-based startup developing antimicrobial products to prevent hospital-acquired infections, has raised $4.1 million from investors in a round that could top out at $5.1 million, according to a new SEC filing.
There are 13 investors in the round, which appears to be the company’s Series B raise. Zurex officials couldn’t immediately be reached for comment.
In 2012, Zurex raised $6.2 million in a Series A round led by Baird Venture Partners and the State of Wisconsin Investment Board, with participation by Wisconsin Investment Partners, Peak Ridge Capital, and individual investors.
Zurex is working on three products: two that focus on catheter-related bloodstream infections and one that would avert infections in surgical wounds.
The company was spun out of Ash Access Technology in 2010, the Wisconsin State Journal reported. Lafayette, IN-based Ash is developing both antimicrobial therapies and medical devices targeting catheter-related bloodstream infections and poor blood flow. Ash also has a Madison, WI, office.
Zurex CEO Carmine Durham previously was Ash’s vice president of corporate development and commercial strategy, and before that he held the same role with Bone Care International in Madison. Bone Care was acquired by Genzyme for $719 million in 2005.
Zurex also has a subsidiary, Zurex PharmAgra, that already sells related products in the agricultural and veterinary markets, such as sanitizers that protect cow teats from bacteria.
